The private equity firm typically cashes out after five years, often through the sale of the company or when the business brings on another investor.

But with lower yields, will investors continue to dabble in bonds, or will they switch their attention to other equity-like assets?

That may be fine with Roche’s patient founding family, which controls the firm thanks to its dual-share structure, but it could dismay other investors.